TY - JOUR
T1 - Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis
AU - Strijkers, Gustav J.
AU - Kluza, Ewelina
AU - Van Tilborg, Geralda A.F.
AU - Van Der Schaft, Daisy W.J.
AU - Griffioen, Arjan W.
AU - Mulder, Willem J.M.
AU - Nicolay, Klaas
N1 - Funding Information:
Acknowledgments This study was funded in part by the Integrated EU Project MEDITRANS (FP6-2004-NMP-NI-4/IP 026668-2), the European Community EC-FP6-project DiMI, LSHB-CT-2005-512146 and by the BSIK program entitled Molecular Imaging of Ischemic Heart Disease (project number BSIK03033). This study was performed in the framework of the European Cooperation in the field of Scientific and Technical Research (COST) D38 Action Metal-Based Systems for Molecular Imaging Applications.
PY - 2010/6
Y1 - 2010/6
N2 - Angiogenesis is essential for tumor growth and metastatic potential and for that reason considered an important target for tumor treatment. Noninvasive imaging technologies, capable of visualizing tumor angiogenesis and evaluating the efficacy of angiostatic therapies, are therefore becoming increasingly important. Among the various imaging modalities, magnetic resonance imaging (MRI) is characterized by a superb spatial resolution and anatomical soft-tissue contrast. Revolutionary advances in contrast agent chemistry have delivered versatile angiogenesis-specific molecular MRI contrast agents. In this paper, we review recent advances in the preclinical application of paramagnetic and fluorescent liposomes for noninvasive visualization of the molecular processes involved in tumor angiogenesis. This liposomal contrast agent platform can be prepared with a high payload of contrast generating material, thereby facilitating its detection, and is equipped with one or more types of targeting ligands for binding to specific molecules expressed at the angiogenic site. Multimodal liposomes endowed with contrast material for complementary imaging technologies, e.g., MRI and optical, can be exploited to gain important preclinical insights into the mechanisms of binding and accumulation at angiogenic vascular endothelium and to corroborate the in vivo findings. Interestingly, liposomes can be designed to contain angiostatic therapeutics, allowing for image-supervised drug delivery and subsequent monitoring of therapeutic efficacy.
AB - Angiogenesis is essential for tumor growth and metastatic potential and for that reason considered an important target for tumor treatment. Noninvasive imaging technologies, capable of visualizing tumor angiogenesis and evaluating the efficacy of angiostatic therapies, are therefore becoming increasingly important. Among the various imaging modalities, magnetic resonance imaging (MRI) is characterized by a superb spatial resolution and anatomical soft-tissue contrast. Revolutionary advances in contrast agent chemistry have delivered versatile angiogenesis-specific molecular MRI contrast agents. In this paper, we review recent advances in the preclinical application of paramagnetic and fluorescent liposomes for noninvasive visualization of the molecular processes involved in tumor angiogenesis. This liposomal contrast agent platform can be prepared with a high payload of contrast generating material, thereby facilitating its detection, and is equipped with one or more types of targeting ligands for binding to specific molecules expressed at the angiogenic site. Multimodal liposomes endowed with contrast material for complementary imaging technologies, e.g., MRI and optical, can be exploited to gain important preclinical insights into the mechanisms of binding and accumulation at angiogenic vascular endothelium and to corroborate the in vivo findings. Interestingly, liposomes can be designed to contain angiostatic therapeutics, allowing for image-supervised drug delivery and subsequent monitoring of therapeutic efficacy.
KW - Angiogenesis
KW - Angiostatic therapy
KW - Liposomes
KW - Magnetic resonance imaging
KW - Molecular imaging
KW - Synergistic targeting
KW - Tumor
UR - http://www.scopus.com/inward/record.url?scp=77955655927&partnerID=8YFLogxK
U2 - 10.1007/s10456-010-9165-1
DO - 10.1007/s10456-010-9165-1
M3 - Review article
C2 - 20390447
AN - SCOPUS:77955655927
SN - 0969-6970
VL - 13
SP - 161
EP - 173
JO - Angiogenesis
JF - Angiogenesis
IS - 2
ER -